Quantcast
Home > Quotes > IMRN

Immuron Limited American Depositary Shares (IMRN) Quote & Summary Data

IMRN 
$7.28
*  
0.4868
7.17%
Get IMRN Alerts
*Delayed - data as of Mar. 19, 2019  -  Find a broker to begin trading IMRN now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    IMRN Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
20
Today's High / Low
$ 7.3461 / $ 6.75
Share Volume
2,354
50 Day Avg. Daily Volume
1,859
Previous Close
$ 6.7932
52 Week High / Low
$ 14.29 / $ 5.2638
Market Cap
26,065,254
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
-0.11

Intraday Chart

Shares Traded

Share Volume:
2,354
50 Day Avg. Daily Volume:
1,859

Trading Range

The current last sale of $7.28 is 38.30% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 7.3461 $ 14.29
 Low: $ 6.75 $ 5.2638

Company Description (as filed with the SEC)

We were incorporated under the laws of the Commonwealth of Australia in 1994 and have been listed on the Australian Securities Exchange (ASX) since April 30, 1999. Our principal executive office is located at Level 3, 62 Lygon Street, Carlton South, Victoria, Australia 3053 and our telephone number is +61 (0)3 9824 5254. We are a clinical-stage biopharmaceutical company with a proprietary technology platform focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies that we believe can address significant unmet medical needs. Our oral polyclonal antibodies offer targeted delivery within the gastrointestinal (GI) track but do not cross into the bloodstream, potentially leading to much improved safety and tolerability, without sacrificing efficacy. We believe that our two lead immunomodulator product candidates, IMM-124E and IMM-529, have the potential to transform the existing treatment paradigms for NASH and for C.  ... More ...  



Risk Grade

Where does IMRN fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 6.76
Open Date:
Mar. 19, 2019
Close Price:
$ 7.28
Close Date:
Mar. 19, 2019


Consensus Recommendation

Analyst Info